A Phase I Study of Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-4394 Injection in Subjects With Prostate Cancer
Latest Information Update: 29 Jan 2025
Price :
$35 *
At a glance
- Drugs SHR 4394 (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions
- Sponsors Jiangsu Hengrui Medicine Co.
- 29 Jan 2025 New trial record